We led the migration of a mission-critical R&D portfolio management system and 60+ custom reports to a cloud environment, ensuring continuity and data integrity.
Challenge
A global biopharmaceutical leader faced the urgent decommissioning of its legacy R&D Portfolio Management platform. The system tracked a 10-year pipeline of Phase I–IV activity, including major discovery milestones, clinical trial activity, filing deadlines, and the path to launch. With multiple cloud-first initiatives underway, the complexity was compounded by concurrent Microsoft Office and Windows upgrades, SharePoint-based collaboration, and custom reporting dependencies. The risk to data continuity and operational efficiency was significant.
Solution
The team orchestrated a full-scale migration of the PMIS to a secure cloud platform. This included over 100 schedules and SharePoint sites, and converting Microsoft SSRS reports. We established a cross-functional governance framework and aligned our approaches with the client’s project and quality management frameworks. We also synchronized IT, business, and R&D stakeholders in North America, India, UK, and Japan. Our team provided end-to-end project leadership, technical acumen, and adoption & change management.
Outcome
Our strategic leadership enabled the client to decommission its legacy portfolio management tool and avoid additional vendor support fees. The successful migration ensured that over $1B in R&D research activity would move forward unencumbered and continue to allow a global team of strategists, researchers, scientists and clinicians to collaborate. The engagement exemplifies our ability to deliver complex digital transformations with measurable business impact.
The migration was completed on time and within budget, with zero data loss. The client continued to leverage the R&D portfolio tool and was unaffected by the decommissioning of the legacy environment.
